Table 2 The baseline characteristics of cirrhotic patients with HCC in training and validation cohort
Clinical parameters | Training cohort (n = 450, %) | Validation cohort (n = 225, %) | P-value |
|---|---|---|---|
Gender, male | 374 (86.2) | 176 (81.1) | 0.092 |
Age, ≥ 60 y | 96 (22.2) | 50 (23.0) | 0.214 |
HBV-DNA, ≥ 103 copies/mL | 246 (56.8) | 137 (63.0) | 0.367 |
HBeAg, positive | 95 (21.9) | 49 (22.6) | 0.366 |
AFP, ≤ 20 ng/mL | 173 (40.0) | 83 (38.4) | 0.866 |
AFP, 20–400 ng/mL | 146 (33.7) | 72 (33.3) | |
AFP, ≥ 400 ng/mL | 114 (26.3) | 61 (28.2) | |
WBC, ≥ 4 × 109/L | 174 (40.0) | 84 (38.5) | 0.498 |
NEU, ≥ 3.56 × 109/L | 156 (36.0) | 74 (34.3) | 0.657 |
LYM, ≥ 1.1 × 109/L | 327 (75.3) | 160 (73.6) | 0.632 |
PLT, ≥ 100 × 109/L | 266 (61.3) | 132 (60.8) | 0.909 |
PT, ≥ 12.8 s | 125 (28.7) | 55 (25.1) | 0.388 |
INR, ≥ 1.15 | 115 (26.5) | 51 (23.5) | 0.408 |
Fib, ≥ 2 g/L | 346 (79.6) | 173 (79.9) | 0.942 |
TB, ≥ 28 μmol/L | 28 (6.5) | 7 (3.2) | 0.084 |
ALT, ≥ 50 IU/L | 168 (38.7) | 63 (29.0) | 0.015 |
AST, ≥ 40 IU/L | 229 (52.8) | 93 (42.9) | 0.017 |
ALB, ≥ 40 g/L | 274 (63.1) | 130 (59.9) | 0.424 |
GGT, ≥ 60 IU/L | 216 (49.8) | 101 (46.5) | 0.438 |
Child–pugh, Stage B | 8 (1.8) | 1 (0.5) | 0.285 |
Tumor diameter, mean (SD), cm | 5.65 (3.35) | 5.28 (3.03) | 0.178 |
Tumor number, multiple | 73 (16.9) | 36 (16.6) | 0.931 |
Differentiation, III + IV | 188 (43.4) | 93 (42.9) | 0.771 |
MVI, present | 166 (38.2) | 63 (29.0) | 0.02 |
Satellite, present | 56 (12.9) | 24 (11.1) | 0.493 |
Type of hepatectomy, anatomic | 185 (42.7) | 92 (42.3) | 0.916 |
Blood loss, ≥ 400 mL | 337 (86.8) | 163 (75.0) | 0.329 |
Transfusion, yes | 67 (15.4) | 38 (17.5) | 0.523 |